1. Introduction {#sec1}
===============

Ankylosing spondylitis (AS) is an immune-mediated chronic inflammatory form of arthritis and is characterized by chronic nonspecific inflammation and pathological bone formation, the latter representing a common clinical form of spondyloarthritis (SpA) \[[@B1]\]. The incidence of AS in China is approximately 0.3% and predominantly affects adults (mean age: 25 years; range: 15--35 years) \[[@B2]\]. Chronic inflammation of the spinal joints can lead to severe chronic pain and stiffness, ultimately leading to bone stiffness in the spine; this can also exert impact on several other systems \[[@B3]\]. AS is characterized by chronic progressive and refractory characteristics and can cause irreversible damage to the central axis of the spine; this results in the spine fusing with the sacroiliac joint, thus resulting in reduced spinal activity \[[@B4]\]. AS exerts serious effects on a patient\'s quality of life and is associated with a significant economic burden to society and families. Previous research suggested that this disease is highly correlated with the MHC (major histocompatibility complex) class I gene, HLA-B27 \[[@B5]\]. However, the specific cause of AS remains unclear, and therapeutic options for the treatment of AS remain inadequate. Over the last decade, new biological agents have been developed that have had a profound effect on the success rates of AS treatment. However, approximately 30% of patients fail to tolerate these drugs or experience differing degrees of adverse reactions \[[@B6]\]. Therefore, there is an urgent need to identify new biomarkers that may act as diagnostic or prognostic indicators for AS. The discovery of such biomarkers is likely to prove invaluable in the prevention, treatment, and control of this disease.

Previous researches involving the identification of molecular mechanisms and novel biomarkers associated with cancer, stroke, and diabetes have involved mRNA expression profiling performed by microarray analysis or high-throughput RNA sequencing \[[@B7]--[@B10]\]. Other studies have described the application of high-throughput technology for autoimmune diseases, such as systemic lupus erythematosus, autoimmune thyroid, and rheumatoid arthritis \[[@B11]--[@B14]\]. High-throughput methodology has already been used to study AS \[[@B15]\]; however, this previous study only focused on synovial tissue \[[@B15]\]. In the present study, we used RNA sequencing to construct a protein-coding gene regulation network in peripheral blood mononuclear cells (PBMCs) isolated from AS patients and healthy controls.

2. Material and Methods {#sec2}
=======================

2.1. Patients and Controls {#sec2.1}
--------------------------

Fifteen patients with AS were recruited from the Department of Rheumatology of the First Affiliated Hospital of Anhui University of Chinese Medicine. These patients were diagnosed by visiting staff according to the American College of Rheumatology (ACR) modified New York criteria \[[@B16], [@B17]\]. In addition, we also recruited 15 age- and sex-matched healthy subjects as controls. None of the patients or controls had any previous history of cardiovascular disease, diabetes, hepatitis, malignancy, or other autoimmune and inflammatory illnesses. The study was approved by the Medical Ethics Committee of the First Affiliated Hospital of Anhui University of Chinese Medicine (2015AH-20).

2.2. RNA Extraction and Sequencing {#sec2.2}
----------------------------------

PBMCs were isolated from AS patients and healthy controls by Ficoll density gradient centrifugation and Lymphoprep (Stemcell, USA). Separated PBMCs were then lysed by a TRIzol Reagent (Invitrogen, USA) and stored at -80°C to await further processing. Total RNA was then extracted using a mirVana miRNA Isolation Kit (Ambion, Foster City, CA) in accordance with the manufacturer\'s instructions. A NanoDrop 2000 (Thermo Fisher Scientific, Waltham, MA) was used to evaluate the quantity of RNA, and an Agilent 2100 bioanalyzer (Agilent Technologies, Santa Clara, CA) was used to assess RNA quality. Purified libraries were prepared by Illumina TruSeq Stranded Total RNA Sample Preparation Kits (Illumina, San Diego, CA) in accordance with the manufacturer\'s instructions and quantified with a Qubit 2.0 Fluorometer (Life Technologies, Carlsbad, CA) and an Agilent 2100 bioanalyzer. cBot software was used to generate a cluster from libraries. The cluster was then sequenced on the Illumina HiSeq 2500 platform (San Diego, CA). All sequencing was performed by Origin-Biotech Inc. (Ao-Ji Bio-Tech, Shanghai, China).

2.3. Analysis of DEGs {#sec2.3}
---------------------

FastQC was used to perform quality control assessments on raw sequence data arising from high-throughput sequencing pipelines (<http://bioinformatics.babraham.ac.uk/projects/fastqc>). Known Illumina TruSeq adapter sequences, poor reads, and ribosome RNA reads were trimmed by seqtk (<https://github.com/lh3/seqtk>) and mapped to the *Homo sapiens* reference genome (hg38) by HISAT2 software (version: 2.0.4) \[[@B18], [@B19]\]. Gene count was then analyzed by StringTie \[[@B19], [@B20]\] and normalized by the trimmed mean of M value (TMM) method \[[@B21]\]. We also determined the number of fragments per kilobase of transcript per million mapped reads (FPKM) using Perl script \[[@B22]\]. Differentially expressed genes (DEGs) were then determined by edgeR \[[@B23], [@B24]\] with a threshold of *p* \< 0.05 and absolute values of log2(fold change) \> 1 \[[@B7], [@B25], [@B26]\].

2.4. Functional Enrichment Analysis {#sec2.4}
-----------------------------------

Next, we aimed to gain a better understanding of the functionality of the DEGs identified. To do this, we used the R package (v 3.5.1) \[[@B27]\] and clusterProfiler to perform GO term enrichment analysis \[[@B28], [@B29]\] and KEGG \[[@B30]\] pathway analysis.

2.5. Protein-Protein-Interaction (PPI) Network Construction and Module Analysis {#sec2.5}
-------------------------------------------------------------------------------

Next, we used the STRING tool \[[@B31]\] to map PPIs for all DEGs with a composite interaction score ≥ 0.4.

Cytoscape \[[@B32]\] was used to visualize the PPI network, and modules were filtered by the Molecular Complex Detection (MCOD) plug-in \[[@B33]\] using the following parameters: degree cut − off = 2, *k* − core = 2, node score cut − off = 0.2, and max depth = 100. Functional enrichment within each module was considered if the MCODE score was ≥4 and the node frequency was ≥10. GO and KEGG enrichment analysis for the DEGs within the four modules was performed in clusterProfiler.

2.6. Validation of DEGs {#sec2.6}
-----------------------

Quantitative real-time polymerase chain reaction (qRT-PCR) was used to verify the RNA sequencing data using *β*-actin as the internal control. Relative mRNA expression was calculated by the 2^-*ΔΔ*CT^ method \[[@B34]\]. In total, the expression levels of six genes were quantified (*TNFAIP3*, *IL1β*, *IL6*, *GPR55*, *CCR2*, and *CXCL5*). The primers used for qRT-PCR are shown in [Table 1](#tab1){ref-type="table"}.

2.7. Statistical Analysis {#sec2.7}
-------------------------

Data are presented as the mean ± standard error of the mean. Data were analyzed using Student\'s *t*-test. *p* \< 0.05 was considered to indicate a statistically significant difference. Student\'s *t*-test and ROC were analyzed by GraphPad Prism (version 8) and presented as the mean ± standard error of the mean.

3. Results {#sec3}
==========

3.1. Screening of DEGs {#sec3.1}
----------------------

In total, 973 DEGs were identified between the AS and control groups, including 644 upregulated DEGs and 329 downregulated DEGs. These DEGs are represented by volcano and scatter plots in Figures [1(a)](#fig1){ref-type="fig"} and [1(b)](#fig1){ref-type="fig"}, respectively. [Figure 2](#fig2){ref-type="fig"} shows the hierarchical clustering of DEGs. The most significant upregulated genes were T cell differentiation protein 2 (*MAL2*) and myomesin 2 (*MYOM*). The top 20 up- and downregulated DEGs are shown in Tables [2](#tab2){ref-type="table"} and [3](#tab3){ref-type="table"}.

3.2. GO and Pathway Enrichment Analysis {#sec3.2}
---------------------------------------

Next, we used clusterProfiler to perform GO enrichment analysis for the 973 DEGs. GO analysis placed the DEGs into 53 subclasses; [Figure 3](#fig3){ref-type="fig"} shows the top 30 subclasses.

GO analysis revealed that the identified DEGs were predominantly associated with a range of biological processes, including positive regulation of the epidermal growth factor-activated receptor activity, positive regulation of the ERBB signaling pathway, the differentiation of trophoblast giant cells, and oxygen transport. In terms of cellular components, the NF-*κ*B complex was dominant. With regard to molecular function, our analyses identified epidermal growth factor receptor binding and CXCR chemokine receptor binding ([Figure 3(a)](#fig3){ref-type="fig"}).

Pathway analysis showed that the pathways most closely related to the DEGs were the TNF signaling pathway, the PI3K-Akt signaling pathway, cytokine-cytokine receptor interaction, and the NF-*κ*B signaling pathway ([Figure 3(b)](#fig3){ref-type="fig"}).

3.3. PPI Network Analysis {#sec3.3}
-------------------------

The DEGs identified in our analysis were then used to build a PPI network based on string databases ([Figure 4(a)](#fig4){ref-type="fig"}). The PPI network consisted of 768 nodes and 3824 edges. Network analysis showed that hundreds of genes were able to interact with 10 more other genes. In particular, IL6, EGF, and CDH1 were shown to interact with more than 100 genes; node distribution is shown in [Figure 4(b)](#fig4){ref-type="fig"}. In total, 29 modules were identified by MCODE, operating with default criteria. [Table 4](#tab4){ref-type="table"} lists these modules in descending order according to MCODE scores \> 2. We selected five modules (modules 1, 2, 3, 4, and 5) with an MCODE score ≥ 3 and ≥10 nodes for module network visualization ([Figure 5](#fig5){ref-type="fig"}).

3.4. Verification of DEGs by qRT-PCR {#sec3.4}
------------------------------------

Compared with the control group, qRT-PCR detected significantly higher levels of expression for *TNFAIP3*, *IL1β*, and *IL6*, in the group of AS patients ([Figure 6](#fig6){ref-type="fig"}). AS patients also had lower expression levels of *GPR55*, *CCR2*, and CXCL5; this was consistent with the results derived from RNA sequencing, thus indicating that the qRT-PCR verification was reliable.

3.5. Receiver Operating Characteristic (ROC) Curve Analysis of Confirmed mRNAs in PBMCs {#sec3.5}
---------------------------------------------------------------------------------------

ROC curve analysis was used to evaluate the potential diagnostic value of differentially expressed mRNAs that showed statistical significance. Our analysis showed that the levels of *TNFAIP3*, *IL1β*, *IL6*, *GPR55*, and *CXCL5* could discriminate between AS patients and controls. Analysis showed that *IL6* had the highest area under the curve (AUC: 0.9533; 95% confidence interval \[CI\]: 0.8872-1.019; *p* \< 0.0001), followed by *IL1β* (AUC: 0.92; 95% CI: 0.8231-1.017; *p* \< 0.0001), *GPR55* (AUC: 0.9089; 95% CI: 0.8041-1.014; *p* = 0.0001), *CXCL5* (AUC: 0.8778; 95% CI: 0.7508-1.005; *p* = 0.0004), and *TNFAIP3* (AUC: 0.7511; 95% CI: 0.5731-0.9291; *p* = 0.0191). Therefore, our analyses suggested that *IL6* (*p* \< 0.0001) may be more valuable than the other four mRNAs as a biomarker for AS diagnosis ([Figure 7](#fig7){ref-type="fig"}).

4. Discussion {#sec4}
=============

In the present study, we used high-throughput RNA sequencing to analyze protein-coding mRNA expression profiles in PBMCs isolated from AS patients and controls. We successfully identified 973 DEGs and then performed a range of analyses (GO, KEGG pathway, PPI, and PPI module) in an attempt to identify novel mechanisms for AS.

GO and pathway enrichment analysis revealed that numerous genes, associated with immune or inflammatory responses, may play a key role in AS. PPI results further demonstrated that the related genes have high degree. Our analysis also revealed that a number of GO terms were enriched, including positive regulation of acute inflammatory response (*p* = 3.170*e*‐03), acute inflammatory response (*p* = 7.623*e*‐05), positive regulation of inflammatory response (*p* = 1.247*e*‐03), regulation of acute inflammatory response (*p* = 8.621*e*‐03), regulation of inflammatory response (*p* = 1.988*e*‐05), inflammatory response (*p* = 3.196*e*‐09), negative regulation of inflammatory response (*p* = 3.462*e*‐02), immune system process (*p* = 4.903*e*‐03), T cell differentiation involved in immune response (*p* = 7.247*e*‐03), negative regulation of immune system process (*p* = 7.468*e*‐03), type 2 immune response (*p* = 8.962*e*‐03), regulation of immune system process (*p* = 9.386*e*‐03), immune system development (*p* = 1.139*e*‐02), response to immobilization stress (*p* = 1.267*e*‐02), regulation of type 2 immune response (*p* = 1.693*e*‐02), T cell activation involved in immune response (*p* = 1.993*e*‐02), leukocyte activation involved in immune response (*p* = 4.212*e*‐02), and cell activation involved in immune response (*p* = 4.525*e*‐02) \[[@B35]--[@B37]\]. We also identified several pathways that were enriched, including the NF-*κ*B signaling pathway (*p* = 3.288*e*‐05), TNF signaling pathway (*p* = 2.309*e*‐05), NOD-like receptor signaling pathway (*p* = 3.995*e*‐03), Salmonella infection (*p* = 7.149*e*‐04), rheumatoid arthritis (*p* = 9.785*e*‐04), cytokine-cytokine receptor interaction (*p* = 4.056*e*‐06), cell adhesion molecules (CAMs) (*p* = 5.342*e*‐04), focal adhesion (*p* = 4.886*e*‐03), and the chemokine signaling pathway (*p* = 1.994*e*‐02) \[[@B38]--[@B40]\]. Some clinical drugs have been reported to target TNFA (tumor necrosis factor alpha) \[[@B38], [@B39]\]; [Figure 8(a)](#fig8){ref-type="fig"} shows the results of our analysis related to the TNF signaling pathway. The present study demonstrated that AS patients are associated with cytokine disorders, excessive activation of NF-*κ*B signaling pathways, increased secretion of inflammatory cytokines, immune complex deposition, and immune-mediated inflammation \[[@B41]\]. Our screening results for the NF-*κ*B signaling pathway are shown in [Figure 8(b)](#fig8){ref-type="fig"}. We hypothesize that AS could lead to immune disorders by regulating the differentiation and activation of T cells and other modes of immunization. Further research is now warranted to identify the specific function of these processes in AS.

In addition, we used qRT-PCR to identify several genes that are related to AS, including *TNFAIP3*, *IL1β*, *IL6*, *GPR55*, and *CXCL5*. The results of our qRT-PCR provided further verification that our high-throughput sequencing results were reliable. Our results also suggest that these genes could effectively distinguish between samples from AS patients and normal controls, thus providing a useful diagnostic tool.

5. Conclusions {#sec5}
==============

Collectively, our findings provide clinically useful information relating to the mRNA profile of PBMCs in patients with AS. In addition, bioinformatic methodology was used to predict the potential functional roles of DEGs and explore their possible roles in the pathogenesis of AS. This information is likely to provide us with a better understanding of the pathogenic processes leading to AS. Future research should be aimed at investigating the specific biological functions and molecular mechanisms underlying the roles of these DEGs in the pathogenesis of AS.
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![Volcano plot (a, blue and red indicate \>twofold decreased and increased expression in AS, respectively) and scatter plot (b, blue and red indicate \>twofold decreased and increased expression in AS, respectively) of DEGs between the AS and control groups. Gray indicates no significant difference.](BMRI2020-5304578.001){#fig1}

![Hierarchical clustering of differentially expressed genes between the AS and control groups.](BMRI2020-5304578.002){#fig2}

![GO and pathway enrichment analysis results for DEGs. (a) Top 30 GO enrichment terms. (b) Top 30 pathway enrichment terms.](BMRI2020-5304578.003){#fig3}

![Visualization (a) and node degree distribution (b) of the PPI network. Node size is related to node degree; pink and green nodes denote up- and downregulated genes, respectively.](BMRI2020-5304578.004){#fig4}

![Significant module 1 (a), module 2 (b), module 3 (c), module 4 (d), and module 5 (e) subnet work of PPI networks. Pink and green nodes denote up- and downregulated genes, respectively. PPI: protein-protein interaction; DEGs: differentially expressed genes.](BMRI2020-5304578.005){#fig5}

![qRT-PCR verification of DEGs. Brain tissue expression of six genes was detected by qRT-PCR and is shown as expression fold changes. GAPDH was the internal control.](BMRI2020-5304578.006){#fig6}

![Visualization and details of the ROC curve.](BMRI2020-5304578.007){#fig7}

![Significantly enriched KEGG pathways in the (a) TNF signaling pathway and (b) NF-*κ*B signaling pathway. Up-DEGs are marked in red. Down-DEGs are marked with dark green. The pictures were drawn with the KEGG Mapper (<http://www.kegg.jp/kegg/tool/map_pathway2.html>).](BMRI2020-5304578.008){#fig8}

  Gene                         Primer sequences             PCR product length (bp)
  ---------------------------- ---------------------------- -------------------------
  GAPDH                        F: ACAACTTTGGTATCGTGGAAGG    101
  R: GCCATCACGCCACAGTTTC                                    
  IL6                          F: ACTCACCTCTTCAGAACGAATTG   149
  R: CCATCTTTGGAAGGTTCAGGTTG                                
  TGFAIP3                      F: TCCTCAGGCTTTGTATTTGAGC    124
  R: TGTGTATCGGTGCATGGTTTTA                                 
  IL1*β*                       F: ATGATGGCTTATTACAGTGGCAA   132
  R: GTCGGAGATTCGTAGCTGGA                                   
  CCR2                         F: CCACATCTCGTTCTCGGTTTATC   88
  R: CAGGGAGCACCGTAATCATAATC                                
  CXCL5                        F: GTTCCATCTCGCCATTCATGC     103
  R: GCGGCTATGACTGAGGAAGG                                   
  GPR55                        F: GAAAACCCTACAGTTTGCAGTCC   123
  R: GAGGTGGCAGCATAATCGGG                                   

  Gene name   Description                                               Test          Control       Log2FC        *p* value    Updown
  ----------- --------------------------------------------------------- ------------- ------------- ------------- ------------ --------
  ESRP1       Epithelial splicing regulatory protein 1                  0.167880977   0.005006537   5.067482003   4.27*E*-16   Up
  EFEMP1      EGF containing fibulin extracellular matrix protein 1     0.14670886    0.004273296   5.101462972   8.17*E*-12   Up
  GPRC5A      G protein-coupled receptor class C group 5 member A       0.080655708   0.002331394   5.112511817   1.65*E*-11   Up
  TENM3       Teneurin transmembrane protein 3                          0.050467249   0.001415242   5.156226587   7.20*E*-08   Up
  SYT7        Synaptotagmin 7                                           0.084086967   0.002342832   5.165557022   3.91*E*-08   Up
  TBX2        T-box 2                                                   0.06419033    0.001648608   5.283036021   1.28*E*-08   Up
  ACOD1       Aconitate decarboxylase 1                                 0.207837546   0.004784204   5.441033669   8.91*E*-05   Up
  KRT18       Keratin 18                                                4.672652849   0.102993604   5.503615208   1.74*E*-51   Up
  CYP24A1     Cytochrome P450 family 24 subfamily A member 1            0.10699757    0.002094784   5.674632992   6.53*E*-07   Up
  SLC7A2      Solute carrier family 7 member 2                          0.091208901   0.001686833   5.75678535    4.33*E*-14   Up
  IGFBP5      Insulin-like growth factor binding protein 5              0.306887146   0.005578492   5.78168917    1.25*E*-20   Up
  TPD52L1     Tumor protein D52 like 1                                  0.054860254   0.0009603     5.836132086   1.31*E*-10   Up
  ASS1        Argininosuccinate synthase 1                              0.498890617   0.008439794   5.885371886   1.55*E*-18   Up
  NPNT        Nephronectin                                              0.111594596   0.001448034   6.268027541   2.07*E*-13   Up
  EMP2        Epithelial membrane protein 2                             0.152045889   0.001923435   6.304677643   1.00*E*-13   Up
  BCAM        Basal cell adhesion molecule (Lutheran blood group)       0.134791483   0.001698518   6.310308799   2.55*E*-14   Up
  MYH14       Myosin heavy chain 14                                     0.113204752   0.00130165    6.442449138   9.53*E*-17   Up
  GFRA1       GDNF family receptor alpha 1                              0.143605056   0.001274655   6.815855972   1.86*E*-22   Up
  KRT8        Keratin 8                                                 2.717254001   0.01760557    7.26997371    1.22*E*-64   Up
  MAL2        MAL, T cell differentiation protein 2 (gene/pseudogene)   0.599737909   0.003393226   7.465531038   1.67*E*-23   Up

  Gene name   Description                                                 Test          Control       Log2FC         *p* value     Updown
  ----------- ----------------------------------------------------------- ------------- ------------- -------------- ------------- --------
  MYOM2       Myomesin 2                                                  0.083396198   2.342960807   -4.812207394   1.32*E*-10    Down
  CCL14       C-C motif chemokine ligand 14                               0.00720548    0.153612496   -4.414057235   7.88*E*-07    Down
  PPARGC1A    PPARG coactivator 1 alpha                                   0.000951005   0.017674014   -4.216033153   0.001331584   Down
  LUM         Lumican                                                     0.003716002   0.067922087   -4.192057583   0.009079935   Down
  FABP4       Fatty acid binding protein 4                                0.011695583   0.173777145   -3.893202651   0.001508377   Down
  SMIM17      Small integral membrane protein 17                          0.013930292   0.201150581   -3.851978548   0.035328047   Down
  FUT2        Fucosyltransferase 2                                        0.002487863   0.035674354   -3.841908383   0.019476857   Down
  GPR20       G protein-coupled receptor 20                               0.019006288   0.264915922   -3.800985884   0.000574724   Down
  HCRT        Hypocretin neuropeptide precursor                           0.029753156   0.396891741   -3.737630912   0.02520749    Down
  COL1A2      Collagen type I alpha 2 chain                               0.001038445   0.013406383   -3.690423438   0.007386025   Down
  SCN5A       Sodium voltage-gated channel alpha subunit 5                0.001175881   0.014594963   -3.633657068   0.011433094   Down
  SRPK3       SRSF protein kinase 3                                       0.002625025   0.030372663   -3.532370079   0.016367701   Down
  CCDC144NL   Coiled-coil domain containing 144 family, N-terminal-like   0.004291893   0.04874123    -3.505456706   0.047045652   Down
  CROCC2      Ciliary rootlet coiled-coil, rootletin family member 2      0.007272199   0.075178624   -3.369858992   0.000103433   Down
  SLC18A1     Solute carrier family 18 member A1                          0.004546282   0.045121799   -3.311065599   0.022179777   Down
  OXCT2       3-Oxoacid CoA-transferase 2                                 0.017775459   0.174884534   -3.298443983   0.00139065    Down
  PLSCR2      Phospholipid scramblase 2                                   0.015226302   0.124444283   -3.030862467   0.001263976   Down
  BTN1A1      Butyrophilin subfamily 1 member A1                          0.006703082   0.054223075   -3.016010489   0.038536757   Down
  HYDIN       HYDIN, axonemal central pair apparatus protein              0.002046295   0.016428267   -3.005094491   0.021563849   Down
  HSPB9       Heat shock protein family B (small) member 9                0.015111578   0.119979888   -2.989066346   0.028712686   Down

  Cluster   Score    Nodes   Edges   Node IDs
  --------- -------- ------- ------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1         11.129   31      345     CXCL8, CSF3, TLR3, SELE, ICAM1, GNG12, GPR55, ADRA2C, SUCNR1, HCAR1, ADRA2A, TAS2R3, TAS2R4, S1PR5, CXCR6, CCL4L1, CXCL3, CXCL5, CCL3, CXCL12, CXCL2, PTGS2, CCR2, CCL20, CXCL1, EGF, CCL4, IL6, MMP9, IL1A, IL1*β*
  2         4.654    26      121     TIMP1, TMEM132A, SPARCL1, VWA1, FAM20A, TNC, IGFBP5, STC2, MFI2, LAMB1, APOL1, APOA2, NOTUM, PRSS23, TNFAIP3, CCRL2, CCL7, NLRP3, IFNB1, SOCS3, NFKBIA, IL1RN, VEGFC, MMP1, PLAUR, PLAU
  3         3.395    38      129     SNAI1, CLDN3, EPCAM, CD1A, CD83, CD1B, MMRN1, PROS1, ORM1, A2M, SRGN, SDC1, TROAP, DEPDC1, CDKN3, NEK2, CDCA5, SPC25, PBK, CDCA3, CDC25C, CCND1, KRT7, SOX9, COL26A1, COL12A1, PLOD2, COL10A1, BMP2, BMP7, SPARC, NES, TEK, AREG, MET, KRT19, KRT18, KRT8
  4         3.25     28      91      OSM, MUC1, F3, FOSL1, SOD2, CD69, RELB, NFKB2, BCL2A1, FASLG, TBX21, SERPINB2, HIF1A, FGF13, KITLG, EDN1, CDH1, LOX, COL4A3, COL4A2, ITGA11, ITGB8, ITGA10, COL6A3, ITGA2B, ITGB3, COL1A2, COL1A1
  5         3.071    14      43      HCRT, EDN2, UTS2, HRH1, P2RY11, GPR84, SNAP25, CD177, MCEMP1, CEACAM8, FCAR, FRMPD3, GPR68, HCRTR1
  6         2.857    7       20      SOCS6, SPSB4, ASB1, FBXO27, FBXO17, KBTBD6, UBE3D
  7         2.154    13      28      RORC, ULBP3, ULBP2, KLRC2, KIR3DL1, KLRB1, CALB1, ELAVL3, TBR1, MAP2, ENSG00000258947, FABP7, EOMES
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